Fig. 1: Differences in inflammatory/fibrotic phenotypes of AMs based on Ly6C expression.

Gating strategy for AMs (CD45+ CD11b-Siglec-F+ CD11c+ Ly6G-) subpopulation and RGS1 expression in Ly6C−, Ly6Clow, and Ly6Chi AMs (a). The frequency of mouse Ly6C− (b), Ly6Clow (c), and Ly6Chi (d) AMs in total lung cells and total AM changes and RGS1 expression within 2 weeks of tracheal administration of E. coli. At 5 days of E. coli infection, the expression of iNOS and IL-1β (e), activities of cathepsins and MMPs (f), expression of IL-10 and SOCS3 (g), and expression of ARG1 and TGFβ1 (h) in LY6Chi AMs (light green), LY6Clow AMs (dark blue), and LY6C− AMs (red) was assessed. Representative flow cytometry plots (left) and statistical graph (right) are shown; each small circle represents a mouse. The data are shown as the mean ± SD; *p < 0.05 and **p < 0.01 by ANOVA, and “n.s.” indicates not statistically significant. The results at each time point correspond to 3 mice.